Mandate

Vinge advises Isofol in connection with IPO

March 14, 2017

Vinge has advised Isofol Medical AB (publ) in connection with its listing on Nasdaq First North Premier. As a part of the offer, a new issue of shares directed to the general public and institutional investors has been conducted which is expected to generate MSEK 430-473 for Isofol depending on whether an over-subscription option is exercised.

The prospectus is expected to be published on 20 March 2017 and the first day of trading on First North Premier is planned for 4 April 2017. The subscription price in the offer is SEK 29 per share, which corresponds to a value of Isofol of approximately MSEK 487 prior to the offer.

Isofol is an oncology company which clinically develops Modufolin which is a first choice medicament in conjunction with treatment of spread colorectal cancer and is standard therapy in conjunction with high dosage treatment with metotrexat of osteosarcoma. Isofol thus intends to replace the existing folate-based medicaments leukovorin and levoleukovorin, which are currently considered to be the standard treatment within these treatment areas.

Through a worldwide, exclusive license agreement Isofol Medical holds all rights to a global commercialization of Modufolin for cancer treatment as well as access to Merck KGaA’s (Darmstadt, Germany) patent-protected manufacturing process and production capacity.

Vinge’s team primarily consisted of responsible partner Anders Strid, partners Jesper Schönbeck and Magnus Pauli, associates Frida Bäckegren, Natalie Bäck, Petronella Hallberg, Victor Ericsson and company assistant Camilla Andersson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025